Education
About Us
Working with TipRanks
Follow Us
Seer (SEER)
NASDAQ:SEER
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.32Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -18.18%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with significant achievements in customer engagement, expansion, and innovation, counterbalanced by revenue decline, net loss, and macroeconomic challenges. The outlook for 2025 is optimistic with expectations of revenue growth and strategic partnerships, but financial pressures and market uncertainties persist.Company Guidance
During the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call, the company provided guidance for 2025, forecasting revenue between $17 million and $18 million, representing a 24% increase over 2024. The guidance reflects ongoing macroeconomic uncertainties, including potential NIH funding issues, which could impact their government and academic customers—collectively contributing around 30% of 2024's revenue. Seer plans to maintain a gross margin range of 50% to 53% for the year and continue strategic investments in direct sales, with a focus on expanding their global reach and enhancing access to their Proteograph product suite. The company also highlighted the strong demand for their Technology Access Center (STAC) services, which significantly contributed to 2024 revenues despite a challenging CapEx environment. Additionally, Seer aims to achieve free cash flow loss between $40 million and $45 million, leveraging their $300 million in cash and investments while managing costs to reach cash flow breakeven.Strong Customer Engagement and Expansion
Seer served over 135 customers, including 12 large biopharma companies, across 20 countries, and doubled its commercial team in North America. The Seer Technology Access Center (STAC) played a critical role in expanding access to Proteograph data.
Revenue and Financial Stability
Seer ended the year with $14.2 million in revenue and approximately $300 million in cash, cash equivalents, and investments. The company repurchased approximately 6.5 million shares, reducing shares outstanding by about 10%.
Continued Innovation and Validation
The company released 23 new peer-reviewed publications in 2024, showcasing the capabilities of its platform, with multiple preprints in high-impact journals.
Partnerships and Commercial Strategy
Expanded partnership with Thermo Fisher Scientific to co-market and sell the Proteograph product suite, enhancing commercial reach and enabling population-scale studies.
---
SEER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SEER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $2.20 | $2.10 | -4.55% |
| Nov 06, 2024 | $2.07 | $2.22 | +7.25% |
| Aug 08, 2024 | $1.73 | $1.72 | -0.58% |
| May 08, 2024 | $2.23 | $2.06 | -7.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Seer (SEER) report earnings?
Seer (SEER) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Seer (SEER) earnings time?
Seer (SEER) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SEER EPS forecast?
SEER EPS forecast for the fiscal quarter 2025 (Q1) is -0.36.
---